Investments and Fair Value Measurements - Narrative (Details)			3 Months Ended							9 Months Ended		12 Months Ended
	Aug. 18, 2021 USD ($)	Apr. 25, 2019	Oct. 02, 2022 USD ($)	Jul. 03, 2022 USD ($)	Apr. 03, 2022 USD ($)	Jan. 02, 2022 USD ($)	Oct. 03, 2021 USD ($)	Apr. 04, 2021 USD ($)	Mar. 29, 2020 USD ($)	Oct. 02, 2022 USD ($) fund	Oct. 03, 2021 USD ($)	Dec. 29, 2019 USD ($)	Feb. 28, 2021 USD ($)	Jan. 02, 2020 USD ($)
Schedule of Investments [Line Items]
Marketable equity securities			$ 41,000,000			$ 107,000,000				$ 41,000,000
Strategic equity investments, without readily determinable fair values			42,000,000			40,000,000				42,000,000
Loss (gain) on Helix contingent value right										(8,000,000)	$ 30,000,000
Gain on derivative assets related to terminated acquisition										0	26,000,000
Pacific Biosciences of California, Inc (PacBio)
Schedule of Investments [Line Items]
Cash									$ 34,000,000			$ 18,000,000
Business combination, contingent consideration arrangements, maximum outcome														$ 52,000,000
Equity or debt financing to be raised														$ 100,000,000
GRAIL Inc
Schedule of Investments [Line Items]
Contingent value right, terms (in years)	12 years
Covered revenues of GRAIL, contingent consideration liability				$ 32,000,000	$ 32,000,000	32,000,000
Payment for contingent consideration										297,000
Contingent consideration liabilities			387,000,000			615,000,000				387,000,000
Contingent consideration, noncurrent			386,000,000			614,000,000				386,000,000
GRAIL Inc | Payment Rights Of One Billion, Each Twelve Years
Schedule of Investments [Line Items]
Contingent payment rights (as a percent)	2.50%
Business acquisition, contingent value rights, revenue threshold	$ 1,000,000,000
GRAIL Inc | Payment Rights Of Above One Billion, Each Twelve Years
Schedule of Investments [Line Items]
Business acquisition, contingent value rights, revenue threshold	$ 1,000,000,000
Contingent payment rights, second percentage (as a percent)	9.00%
Helix Holdings I, LLC
Schedule of Investments [Line Items]
Contingent value right, terms (in years)		7 years
Loss (gain) on Helix contingent value right			(5,000,000)				$ 12,000,000			$ (8,000,000)	30,000,000
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P
Schedule of Investments [Line Items]
Business combination, contingent consideration arrangements, maximum outcome													$ 52,000,000
Gain on derivative assets related to terminated acquisition								$ 26,000,000
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P | Convertible Senior Notes
Schedule of Investments [Line Items]
Principal amount outstanding													$ 900,000,000
Venture Capital Investment Fund (the Fund)
Schedule of Investments [Line Items]
Number of venture capital investment funds | fund										2
Equity method investments			184,000,000			$ 173,000,000				$ 184,000,000
Unrealized (loss) gain on investments			(5,000,000)				23,000,000			(11,000,000)	54,000,000
Venture Capital Investment Fund (the Fund), One
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund			100,000,000							100,000,000
Remaining capital commitment			11,000,000							11,000,000
Venture Capital Investment Fund (the Fund), Two
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund			150,000,000							150,000,000
Remaining capital commitment			101,000,000							101,000,000
Investee
Schedule of Investments [Line Items]
Revenue from transactions with strategic investees			$ 27,000,000				$ 14,000,000			$ 83,000,000	$ 47,000,000